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Abstract 
Background: Venous thromboembolism (VTE) is an important cause of morbidity and a preventable 
cause of deaths following lower limb joint replacement. Risk prediction scores that help to predict 
individual VTE risk following lower limb joint replacement may inform the development of 
preventive strategies and guide treatment decisions. We aimed to systematically review the evidence 
on the development and/or validation of risk prediction scores for VTE following lower limb joint 
replacement.  
Methods: Population-based studies that have developed and/or validated a risk prediction score for 
VTE following hip or knee replacement and randomized controlled trials (RCTs) that have evaluated 
the clinical impact of a score were searched for in MEDLINE, Embase, Web of Science, and The 
Cochrane Library to April 2018.  
Results: Five observational cohort studies describing five risk scores were included. No RCTs were 
identified. The number of component variables in a single risk score ranged from 5 to 26. Two risk 
scores comprised 5-8 component variables. None of the studies reported calibration or discrimination 
statistics. Two risk scores were externally validated in single-institution cohorts and were reported to 
perform well. One study evaluated the general surgery Caprini risk score in primary hip and knee 
replacement patients and did not find it useful for VTE risk stratification. 
Conclusions: Few VTE risk prediction scores in lower limb joint replacement exist and these have 
methodological issues, have been inadequately reported, not been sufficiently validated, and their 
impact on patient outcomes and decision making is unknown. Research is urgently warranted in the 
field. 
Systematic review registration: PROSPERO 2018: CRD42018088712 
Keywords: risk score; risk prediction; venous thromboembolism; deep vein thrombosis; pulmonary 
embolism; joint replacement; systematic review 
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1. Introduction 
Total joint replacement, one of the most common elective orthopaedic procedures, is a highly 
successful and cost-effective intervention for alleviating pain and disability associated with advanced 
joint disease such as osteoarthritis.[1, 2] Venous thromboembolism (VTE), which comprises 
pulmonary embolism (PE) and deep vein thrombosis (DVT), is a frequent complication of lower limb 
joint replacement. Venous thromboembolism affects several millions of people globally, it is an 
important cause of long-term morbidity and a preventable cause of deaths, and its management is 
associated with huge health costs.[3] Despite the effectiveness of anticoagulants at preventing VTE, 
rates ranging from 0.27% to 61.0% have been reported in patient populations undergoing lower limb 
replacement.[4, 5]  
With increasing life expectancy, there is a predicted large rise in the number of people who will be 
affected by joint disease and hence the number of patients undergoing primary joint replacement.[6] 
Despite the emergence of newer and more potent prophylactic regimens for VTE, there will also be a  
proportionate rise in the number of patients who will be affected by VTE. As such, the most 
appropriate way to tackle this is from a public health perspective – using a preventive approach. This 
entails identifying patients who are at high risk of developing VTE before they undergo joint 
replacement and developing preventative measures targeted at these high-risk groups. There are 
several known predisposing risk factors for VTE development following lower limb joint replacement 
and these include advanced age; high body mass index (BMI); smoking; and comorbidities such as 
cardiovascular disease, previous VTE, and cancer.[7-9] These established risk factors have the 
potential to be used to identify patients who are at high risk of VTE and can also be combined within 
a risk prediction score or prognostic model to predict VTE outcome risk for individuals. A risk 
prediction score is a statistical equation that uses multiple prognostic or risk factors in a formal 
combination to estimate the individualised probability or risk that a certain condition or disease will 
occur in the future.[10] Given that the risk of VTE development after lower limb joint replacement 
varies between individuals, there is an interest in developing individualised risk prediction scores for 
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VTE risk; however, little progress has been made in the area. Much research has been focussed on the 
identification of risk or prognostic factors for VTE in joint replacement patients.[11] Published 
studies have mostly reported on measures of the strength of the association (e.g., odds ratios, risk 
ratios, hazard ratios), which do not address the accuracy of these factors in classifying or predicting 
risk of VTE in individuals following joint replacement.[12]  
 Prevention of VTE following lower limb replacement is a high policy priority and no single 
risk prediction score has as yet been recommended as being optimal for VTE risk prediction in 
orthopaedic practice. It is also known that there is often conflicting evidence about the predictive 
performance of developed risk prediction scores.[13] To our knowledge, there is no summarised 
evidence on existing risk scores (including their component variables), their predictive performance, 
and whether their clinical effectiveness have been assessed in well-designed randomized controlled 
trials (RCTs). In this context, we aimed to systematically review all the available evidence on risk 
prediction scores for VTE following hip and/or knee replacement. The specific objectives were to: (i) 
assess clinical variables selected for model inclusion and the predictive performance of these models; 
(ii) assess if identified models have been externally validated and their performances compared; (iii) 
assess if the clinical effectiveness of these scores have been evaluated in appropriate RCTs; and (iv) 
to identify gaps in the existing evidence and whether further research is needed in the field. Our 
findings should inform clinical practice by identifying host, surgical, and laboratory characteristics 
that show consistent evidence of prognostic significance and should inform further research in this 
area. 
 
Methods 
2.1. Data sources and search strategy 
We conducted this review in accordance with the CHARMS checklist[14] and PRISMA 
guidelines,[15] (Appendix A) and using a predefined protocol, which has been registered in the 
PROSPERO prospective register of systematic reviews (CRD42018088712). We searched for eligible 
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studies in MEDLINE, Embase, Web of Science, and The Cochrane Library electronic databases from 
inception up to 20 April 2018. The computer-based search strategy combined free and MeSH search 
terms and combination of key words relating to risk prediction (e.g., “risk score”, “sensitivity”, 
“prognostic model”), VTE (e.g., “venous thromboembolism”, “deep vein thrombosis”, “pulmonary 
embolism”), and joint replacement (e.g., “hip replacement”, “knee replacement”, “joint arthroplasty”). 
There were no language restrictions. We complemented the search by manually scanning reference 
lists of relevant articles and reviews for all relevant additional studies missed by the computerised 
search strategy. Details of the search strategy are provided in Appendix B.  
 
2.2. Eligibility criteria 
The following inclusion criteria were employed for eligibility of studies: (i) population-based 
observational studies (prospective cohort, retrospective cohort, prospective or retrospective case 
control, case-cohort, or nested-case control) that developed or validated a risk prediction score for 
VTE or an update on a previously developed model; (ii) outcome was VTE (DVT or PE) reported in a 
longitudinal design (Since 90% of VTE cases occur within the first post-operative week,[16] we 
considered a minimum of 30 days follow-up duration as acceptable); (iii) included adults > 18 years 
who had been followed up after hip and/or knee replacement surgery; and (iv) RCTs that assessed the 
clinical effectiveness of a VTE risk prediction score in an intervention group compared to usual care 
in a control group. We excluded the following: (i) cross-sectional and clinical case studies; (ii) studies 
with risk prediction scores containing less than two variables; (iii) studies only reporting measures of 
associations between a potential risk factor and the risk of VTE; and (iv) studies conducted in non-
population-based samples. 
 
2.3. Data extraction and quality assessment  
One reviewer (S.K.K.) did an initial screen of titles and abstracts and acquired potentially relevant 
articles for full text evaluation. In any instance where there was confusion regarding eligibility of an 
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article based on title and abstract, that article was always selected for full text evaluation. Two 
independent reviewers (S.K.K., A.D.B.) assessed each article using the inclusion criteria and any 
disagreements regarding eligibility of an article was discussed, and consensus reached with 
involvement of a third reviewer (M.R.W). Data from selected articles was extracted by one reviewer 
(S.K.K.) using a standardized data collection form and quality assessments were also conducted. A 
second reviewer (A.D.B.) independently checked these data with that in original articles. We 
extracted data on first author’s name, study publication date, country and geographical location, study 
design, baseline year, type of population, statistical model or methods employed, sample size, VTE 
outcomes, use of thromboprophylaxis, timing of outcomes, component variables of each risk 
prediction model, measures of discrimination, calibration, and/or reclassification, and reported 
performance comparisons of the model. We also extracted data on details of validation (internal 
and/or external) performance statistics. The risk of bias (quality) of any study developing or 
evaluating a risk prediction score was assessed using a preliminary version of the Prediction study 
Risk Of Bias Assessment Tool (PROBAST), a tool for assessing risk of bias, applicability and 
usability of prognostic models.[17] Briefly, this tool uses information on five pre-defined domains 
namely: participant selection, predictors, outcomes, sample size and patient flow, and analysis. The 
PROBAST evaluation is used to determine the risk of bias of the risk score (i.e., whether the score is 
likely to work as intended for the population of interest), with risk scores classified as low, moderate 
or high risk of bias.  
 
2.4. Data synthesis and analysis 
It was planned to quantitatively summarise the predictive performance (using calibration and 
discriminatory statistics) of models across studies if multiple studies were found to have validated the 
same risk score. This was to summarise the models’ average performances across different settings 
and potential performance in a future setting. However, this was not possible given the limited 
number of studies, type of measures reported, unavailability of relevant summary statistics, and the 
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diversity of the study designs and populations. We were also unable to make effective comparisons of 
risk scores across studies because of the heterogeneity of the data and the variable methodologies 
adopted. The characteristics of each study and risk scores were summarized in tables. A narrative 
synthesis was performed using the data extracted and according to previously reported quality criteria 
for risk scores such as usability (10 or fewer components), good calibration, discriminative ability (> 
0.70), generalizability (externally validated), and clinical effectiveness.[18, 19] 
 
3. Results 
3.1. Study identification and selection 
The flow of studies through the screening and selection process is shown in Figure 1. The literature 
search strategy identified 603 potentially relevant articles. After an initial screen of titles and 
abstracts, 11 articles were selected for full text evaluation. Following detailed evaluation, six articles 
were excluded because (i) they did not report development and/or validation of a specific risk 
prediction score (n=4); (ii) the population was not relevant (n=1); and (iii) the outcome was not 
relevant (n=1). The remaining five articles met the inclusion criteria and were included in the 
review.[20-24]  
 
3.2. Study characteristics and quality assessment 
Table 1 summarizes characteristics of studies included in the review. Identified studies were 
published between 2012 and 2017. The sample size of cohorts ranged from 272 to 1,721,806 hip or 
knee replacements. Overall, the studies comprised 1,867,318 primary or revision hip and knee 
replacements, including 16,675 VTE events. Four studies were conducted in the USA and one in 
France. The average baseline age of participants ranged from 66.5 to 71.6 years for the three studies 
that reported these data. All included studies employed observational cohort designs and sampling 
frames included medical charts, institutional databases, national databases, and joint registries. 
Outcomes reported were VTE in 2 studies, PE in two studies and DVT in one study and all VTE cases 
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were symptomatic. Two studies reported on how the outcome event was defined, diagnosed and 
ascertained.[20, 22] Three studies reported use of post-operative pharmacological VTE 
thromboprophylaxis in patients which comprised a variety of agents including low-molecular-weight 
heparin (LMWH), warfarin, aspirin, and direct thrombin or factor Xa inhibitors (e.g., dabigatran, 
rivaroxaban, apixaban, etc).[20, 23, 24] Two studies reported having no records of the type of VTE 
prophylaxis received;[21, 22] however, one of these studies validated the risk score externally in a 
different population of patients who received warfarin[22] (Table 2). Quality assessment using the 
PROBAST tool showed evidence of high overall risk of bias throughout the included studies. Three 
risk scores had unclear concern for overall applicability and none of the scores were assessed as 
usable in the targeted individuals and context (Appendix C). 
 
3.3. Model description and development 
Table 2 provides details of VTE risk prediction scores described in included reports, statistical 
properties, their component variables, any measures of performance recorded, and reports of any 
validation and performance comparisons made. A total of five risk scores were described in the five 
eligible studies. Three risk scores were derivations of risk models on a base population[20-22] and 
two studies attempted to validate existing risk scores that had been developed in different populations 
or used different outcomes.[23, 24] None of the risk models was developed in a cohort designed for 
this sole purpose; they all retrospectively used data that had been prospectively collected for different 
purposes. Two studies employed logistic regression techniques in their model development[20, 21] 
and one employed Cox regression.[22] The component risk factors varied from score to score and 
ranged in number from 5 to 26. The component variables for the risk scores were based on data that 
could be assessed non-invasively such as demographics, BMI, medical and surgical histories, and 
surgical procedures.  
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3.4. Model diagnostics 
None of studies reported measures of discrimination or calibration for any of the risk scores 
described. Parvizi and colleagues created a nomogram based on eight risk factors to predict the risk of 
PE after hip and knee replacement.[20] However, the study authors did not report on the performance 
of the nomogram. In another study, Parvizi and colleagues used National Inpatient Sample (NIS) 
registry data to develop an individualised risk model for VTE which was based on 26 risk factors.[21] 
The authors used scoring criteria to assess the performance of the model. The authors reported that 
their calibration curve showed a near perfect fit between the predicted VTE rate (using the risk model) 
and the actual rate of VTE in NIS data up to a 5% rate of VTE, beyond which point there was a clear 
divergence. Bohl and colleagues developed a risk stratification system for PE within 30 days of 
primary total hip or knee replacement, using the American College of Surgeons National Surgical 
Quality Improvement Program (ACS-NSQIP) registry data.[22] The risk stratification score, which 
comprised of five simple patient variables, was based on a point-scoring system in which patients 
were assigned as low-, medium-, and high-risk categories. Bateman and colleagues[23] evaluated the 
Caprini Risk Assessment Model (RAM), which was originally developed to estimate VTE risk in the 
general surgical population.[25] The authors reported that this score did not provide clinically useful 
risk stratification for total hip and knee replacement patients. Dauty and colleagues used the Risk 
Assessment and Predictor Tool (RAPT) to evaluate the risk of complications (including DVT) in 
patients following total knee replacement surgery.[24] The RAPT tool is a validated risk score which 
was originally developed to predict a patient's risk of needing extended inpatient rehabilitation 
after hip or knee replacement.[26] Findings from the study suggested that the RAPT tool was 
appropriate in identifying patients who had the most complications (including DVT) and required a 
longer hospital stay. 
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3.5. Model validation 
Only one study reported conducting internal validation using bootstrapping.[20] Two risk scores were 
externally validated using independent datasets in the same studies. The risk score based on NIS data 
was reported to perform well when compared with the independent dataset.[21] The ACS-NSQIP-
derived risk stratification system was externally validated in a single-institution cohort and was 
observed to perform well[22] (Table 2). 
 
3.6. Performance comparisons 
None of the risk scores were compared with existing models.  
 
3.7. Clinical evaluation of risk scores 
None of the studies described the evaluation of the clinical effectiveness of a risk prediction score in 
an intervention study or as part of an impact study aimed at changing patient outcomes. 
 
4. Discussion 
4.1. Key findings 
This systematic review of available risk prediction scores for VTE following hip and knee 
replacement identified five studies, all published in the last six years. Three studies reported the 
development of three independent risk scores,[20-22] whereas two studies evaluated existing scores 
originally developed for different populations or outcomes.[23, 24] Only two studies reported on the 
definitions used for VTE outcomes.[20, 22] The number of component variables for the five risk 
prediction scores ranged from 5 to 26, with three scores having less than 10 components. None of the 
studies reported appropriate calibration or discrimination statistics for the risk scores; however, one 
study reported on a calibration curve which suggested good performance of the model below a 
specific VTE rate.[21] Two of the risk scores were externally validated in independent populations by 
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the authors in the same studies.[21, 22] Quality assessment of the risk scores’ development and 
validation criteria showed all scores to have a high overall risk of bias. This was mainly due to the 
methodology used in assessment of predictors and outcomes, as well as the analyses employed.  
 
4.2. Methodological limitations 
It is evident that there has been little progress in the field of development of risk prediction scores for 
VTE following hip or knee replacement. In addition to the huge gaps in the field, our findings 
highlight the methodological limitations in the development of the identified scores. First, the 
majority of studies did not report on the definitions used for VTE outcomes. This tends to create 
uncertainty as to which populations the proposed risk scores are applicable to. In addition, VTE 
outcomes that are not independently adjudicated and based on database International Classification of 
Diseases (ICD) codes that are not validated, are less accurate. To ensure that risk prediction scores are 
reliable for the intended patients, standard consistent definitions need to be employed.[27] Second, of 
the three studies that reported development of a risk prediction model, none was developed in a cohort 
recruited for this sole purpose, thereby introducing an inherent selection bias. The study designs 
employed retrospective data collected from prospective cohort designs, which are ideal for risk score 
modelling as the risk factor information can be ascertained blindly in relation to the outcome or 
disease.[27] Third, a key methodological issue was that none of the studies reported calibration, 
discrimination, as well as reclassification statistics, which describe the performance of the models. 
This is of great concern given that these measures are very vital in the development of a risk score. 
Calibration, which is measured by the goodness-of-fit statistic, is the ability to accurately estimate the 
risk of a future event (VTE in this case). Discrimination is the ability of the risk prediction score to 
separate individuals at higher risk from those at lower risk of the event of interest; this is assessed 
using the area under the receiver-operating characteristic (ROC) curve or C statistic (Harrell’s C-
index[28]).[29] A C-index of 0.5 represents no improvement over what would be expected by chance, 
whiles a C-index of 1 implies perfect discrimination.[30] Reclassification or risk stratification, which 
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is assessed using the net-reclassification-improvement (NRI)[31, 32] and the integrated-
discrimination-improvement (IDI),[31] is the ability of the risk score to appropriately reclassify 
patients into clinically relevant subgroups. These two measures test the addition of factors to risk 
prediction models. How well these identified risk scores are calibrated and their discriminative 
abilities are not known given the lack of relevant information provided in the studies. Fourth, none of 
the studies provided a clear and detailed report on the treatment of missing data, an issue of relevance 
in the development of risk scores.[10] Bohl and colleagues reported excluding patients with missing 
data on relevant variables.[22] Evidence suggests that risk prediction scores that employ multiple 
imputation technique produce more generalisable models compared with models that ignore such 
additional analyses.[27] Fifth, given that simplicity is an important criteria for developing clinically 
useful risk prediction scores,[33, 34] there are concerns with usability of two of the risk scores, as 
they employed 20-26 variables.[21, 23] Complex models are more likely to provide overoptimistic 
predictions, especially when extensive variable selection has been performed.[35] Sixth, except for 
one study,[20] none of the risk scores was reported to have undergone internal validation, which is a 
process which provides a good indication of how optimistic the risk score may be.[36] Nevertheless, 
despite the importance of internal validation, this process is unable to provide information on the 
performance of the risk score elsewhere or its generalizability. Before a risk prediction tool can be 
effectively employed in clinical practice or in a real world setting, its generalization needs evaluation 
in a new setting (using independent datasets from different locations) – a process known as external 
validation.[10] Two of the studies externally validated their developed risk scores;[21, 22] however, 
none of these risk scores were reported to have been externally validated by a third party, a method 
which is least prone to bias.[37] whiles a third study attempted to validate an existing risk score which 
was not specifically developed for that patient population. Finally, none of the identified risk scores 
was reported to have been evaluated in an impact study to investigate their influence on patient 
outcomes, decision making, and costs, a vital criterion that also needs to be fulfilled before a risk 
score can be implemented in a clinical setting.[10] For a risk score to be adopted in clinical practice, it 
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should be clinically credible, well calibrated with good discriminative ability, should have been 
externally validated, and have real clinical impact.[10, 33, 38]  
 
4.3. Implications of our findings 
Findings from our review suggest the potential value of VTE risk assessment is underappreciated in 
orthopaedic practice. Individualized patient risk assessment to identify VTE risk in surgical patients 
has been very widely advocated.[39-41] Indeed, several risk assessment models have been developed 
to predict VTE risk in surgical patients, but it appears none have been extensively validated or 
clinically evaluated in hip or knee replacement patients. The most widely used VTE risk assessment 
tool in surgical practice is the Caprini Risk Assessment Model (RAM), first described almost three 
decades ago.[25] The original Caprini RAM integrates 20 risk factors (comprising age, genetics, 
medical, and surgical factors) to calculate a cumulative risk score, which is used to group patients into 
risk categories (low, moderate, and high risk). It has since then undergone several modifications and 
refinements as well as validation in both medical and surgical patients.[42-47] In one of the studies 
included in our review, the study authors employed the Caprini RAM in a first attempt to validate it in 
total hip and knee replacement patients. However, the risk model was unhelpful in stratifying VTE 
risk, which the authors attributed to inadequate power to validate. Among the identified risk scores, 
the ACS-NSQIP-derived risk stratification system may be potentially promising for future clinical use 
based on its development from a large dataset, use of five patient characteristics, and having 
undergone external validation. However, in addition to the methodological limitations and lack of 
information on its discriminative ability, its clinical effectiveness is yet to be evaluated and needs to 
undergo further validation in new populations. The limited number of published VTE risk scores 
available for hip or knee replacement patients and lack of data on their performance is a cause for 
great concern. The incidence of VTE is likely to increase in conjunction with growing healthcare 
burden due to osteoarthritis[48] and a predicted large rise in the numbers of hip and knee replacement 
procedures.[49, 50] In the era of preventive medicine, VTE risk assessment should be performed in all 
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patients undergoing lower limb replacement using reliable and well validated risk prediction scores. 
Our findings suggest validated tools are currently non-existent. Researchers and clinicians are 
encouraged to support collaborative efforts to develop and validate appropriate risk prediction scores 
for use in orthopaedic practice.  
 
4.3. Study strengths and limitations 
To our knowledge, this is the first systematic review identifying and summarizing the literature on the 
development and validation of VTE risk prediction scores following hip or knee replacement. Though 
we retrieved a limited number of eligible studies, we employed a comprehensive search strategy 
which spanned multiple databases, making it unlikely that any relevant study was missed. Indeed, this 
study has revealed very large gaps in the research area. We also conducted a detailed assessment of 
the existing risk scores using established criteria. A limitation of our review was that we were unable 
to harmonize data from contributing studies to perform pooled analysis and analysis by subgroups such 
as age, sex, type of joint (hip vs knee), type of VTE (DVT vs PE, symptomatic vs asymptomatic) and 
type of anticoagulant; this was due to the limited number of studies, lack of data on measures of 
performance (e.g., C-index), and substantial heterogeneity between studies. The heterogeneity between 
the included studies was attributable to the different VTE outcomes reported, different 
thromboprophylactic agents used, different percentage of patients with outcomes (ranging from <1% to 
6%) and different follow-up durations. Despite efforts to summarise the data as robustly as possible 
using established criteria, our conclusions might be limited due to the quality of published research and 
the inability of studies to report the results in a way that can be used by clinicians.  
 
5. Conclusions 
Only a small number of risk scores to predict VTE in hip and knee joint replacement patients have been 
developed and these have several limitations. The existing risk scores have been developed using 
inadequate methodology, have been inadequately reported, not been sufficiently validated, and their 
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impact on patient outcomes and decision making is unknown. The ACS-NSQIP-derived risk 
stratification system may have some potential for use in clinical practice; however, inadequate 
methodology was employed in its development, there is lack of detailed information on its 
performance, it has not undergone further validation in new populations, and its clinical impact hasn’t 
been evaluated. Urgent research is encouraged in the field to help develop robust risk prediction 
scores with potential clinical value. 
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Figure legends 
 
Figure 1. PRISMA Flow Diagram. 
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Table 1. Summary characteristics of studies included in the review  
Lead author, 
publication date 
(reference) 
Location Baseline 
year 
Study design Sampling frame Population Anticoagulation and 
dosage 
Mean 
age 
(years) 
Name of risk tool Specific outcome 
reported 
Sample size 
(joint 
replacements 
or patients) 
Number of 
events (%) 
Timing of 
outcome 
             
Dauty, 2012 (24) France 2004-2007 Retrospective 
cohort 
Medical charts Total knee replacement 21-day LMWH in 
preventive enoxaparin 
sodium injections 
71.6 RAPT Symptomatic DVT 272 17 (6.25) NR 
Parvizi, 2014 (20) USA 2000-2011 Observational 
cohort 
Institutional 
orthopaedic database 
Primary and revision total 
hip and knee replacement 
Warfarin for 6 weeks or 
325 mg aspirin twice 
daily 
69.4 NR Symptomatic PE 26,391 281 (1.06) 90 days 
Parvizi, 2016 (21) USA 2002-2011 Observational 
cohort 
NIS data Total hip and knee 
replacement 
NR 40-100‡ NR Symptomatic VTE (DVT 
and PE) 
1,721,806 15,775 (0.92) NR 
Bohl, 2016 (22) USA 2006-2013 Observational 
cohort 
ACS-NSQIP Primary total hip or knee 
replacement 
NR NR ACS-NSQIP-derived 
risk stratification 
system 
Symptomatic PE 118,473 ~592† (0.50) 30 days 
Bateman, 2017 (23) USA 2015-2016 Retrospective 
cohort 
Orthopaedic database Primary total hip or knee 
replacement 
Warfarin, direct 
thrombin or factor Xa 
inhibitors (e.g., 
dabigatran, apixaban, 
10 mg rivaroxaban 
daily), or aspirin 325 
mg twice daily 
66.5 Caprini RAM* Symptomatic VTE (DVT 
and PE) 
376 10 (2.66) 90 days 
ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; NIS, National Inpatient 
Sample; NR, not reported; PE, pulmonary embolism; RAM, risk assessment model; RAPT, Risk Assessment and Predictor Tool; THA, VTE, venous thromboembolism 
*, study employed the Caprini RAM in predicting 90-day postoperative VTE incidence in total joint replacement patients; †, numbers calculated based on percentage provided in the report; ‡, 
age range 
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Table 2. Key characteristics of development and validation of risk prediction scores for venous thromboembolism included in the review  
Lead author, 
publication date 
Name of risk tool Statistical model Predictors used Number of 
predictors 
Discrimination (C- 
index) 
Calibration 
(HL goodness-of-fit test) 
Internal 
validation 
External validation  Performance 
comparison 
          
Dauty, 2012 (24) RAPT NR Age, gender, average walking distance, use of 
gait aid, use of community support and care, 
and social support at discharge 
6 NR NR None None NR 
Parvizi, 2014 (20) NR Logistic regression Knee surgery, CCI, atrial fibrillation, 
postoperative DVT, COPD, anaemia, 
depression, BMI 
8 NR NR Bootstrapping None NR 
 
Parvizi, 2016 (21) NR Logistic regression Bilateral joints, not primary THA, age, 
anaemia, CHF, lymphoma, fluid and 
electrolyte disorders, metastatic cancer, 
peripheral vascular disease, non-metastatic 
solid tumours, weight loss, chronic 
pulmonary heart disease, blood transfusion, 
history of VTE, myeloproliferative disorders, 
hypercoagulability state, myocardial 
infarction, varicose veins, fracture, 
inflammatory bowel disease, sepsis, 
periprosthetic joint infection, atrial 
fibrillation, stroke, apnoea 
26 NR Near perfect goodness of 
fit reported in NIS data up 
to 5% rate of VTE 
None Externally validated in a single-
institution cohort 
NR 
Bohl, 2016 (22) ACS-NSQIP-
derived risk 
stratification 
system 
Cox regression Age, sex, BMI, preoperative haematocrit, and 
procedure type 
5 NR NR None Externally validated in a single-
institution cohort in which all 
patients received warfarin as 
thromboprophylaxis 
NR 
Bateman, 2017 
(23) 
NR NA Age, planned operation >2 hours, history of 
DVT or PE, leg oedema/ulcers/ stasis, sepsis, 
varicose veins, hormone treatment, 
malignancy, previous immobilisation, CVD, 
trauma, fracture, obesity, stroke, major 
surgery, pregnancy, protein C/ antithrombin 
III/ protein S deficiency, plasminogen 
disorders, nephrotic syndrome, paroxysmal 
nocturnal haemoglobinuria, lupus, 
polycythaemia vera, inflammatory bowel 
disease, and other 
20 NR NR None Validation of the Caprini RAM in 
joint replacement patients 
NR 
ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; BMI, body mass index; CCI, Charlson Comorbidity Index; CHF, congestive heart failure; COPD, chronic obstructive 
pulmonary disease; DVT, deep vein thrombosis; NA, not applicable; NR, not reported; RAPT, Risk Assessment and Predictor Tool; THA, total hip arthroplasty; VTE, venous thromboembolism 
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Appendix A. PRISMA checklist 
 
Section/topic 
Item 
No Checklist item 
Reported on 
page No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, 
limitations, conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3-4 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS) 
5 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if 
available, provide registration information including registration number 
5 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such 
as years considered, language, publication status) used as criteria for eligibility, giving rationale 
5 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched 
5 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated 
Appendix 2 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis) 
5 
Data collection 
process 
10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators 
6 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
6 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis 
6 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Not applicable 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (such as I2 statistic) for each meta-analysis 
Not applicable 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication 
bias, selective reporting within studies) 
6 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified 
Not applicable 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram 
7 and Fig. 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, 
follow-up period) and provide the citations 
7-8, Table1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 
12). 
7-8, Appendix 3 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for 
each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
Not applicable  
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency 
Not applicable 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-
regression) (see item 16) 
Not applicable 
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (such as health care providers, users, and policy makers) 
10 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
13 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research 
10-14 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and 
role of funders for the systematic review 
14 
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Appendix B. Literature search strategy 
Relevant studies, published before 20 April 2018 (date last searched), were identified through electronic searches not limited 
to the English language using MEDLINE, EMBASE, Web of Science, and Cochrane databases. Electronic searches were 
supplemented by scanning reference lists of articles identified for all relevant studies (including review articles) and by hand 
searching of relevant journals. The computer-based searches combined search terms related to risk prediction, venous 
thromboembolism, and joint replacement. 
1     exp Venous Thrombosis/ (51140) 
2     venous thrombus.mp. (493) 
3     exp Venous Thromboembolism/ (8174) 
4     exp Pulmonary Embolism/ (36029) 
5     deep vein thrombosis.mp. (14494) 
6     risk score.mp. (11236) 
7     exp Risk Assessment/ (228856) 
8     predict.mp. (286230) 
9     score.mp. (449810) 
10     diagnostic.mp. (737169) 
11     exp "Sensitivity and Specificity"/ (522324) 
12     exp ROC CURVE/ (46410) 
13     receiver operating characteristic.mp. (43083) 
14     exp Area Under Curve/ (35130) 
15     C statistic.mp. (3339) 
16     C-index.mp. (1879) 
17     concordance statistic.mp. (105) 
18     prognostic.mp. (238170) 
19     exp Algorithms/ (273054) 
20     model.mp. (1744458) 
21     calculator.mp. (3012) 
22     exp ARTHROPLASTY/ (56897) 
23     exp Arthroplasty, Replacement/ (45495) 
24     joint arthroplasty.mp. (3488) 
25     total arthroplasty.mp. (359) 
26     exp Arthroplasty, Replacement, Knee/ (19139) 
27     exp Arthroplasty, Replacement, Hip/ (22802) 
28     exp Arthroplasty, Replacement, Ankle/ (553) 
29     exp Arthroplasty, Replacement, Shoulder/ (380) 
30     1 or 2 or 3 or 4 or 5 (90506) 
31     6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 (3826985) 
32     22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 (58398) 
33     30 and 31 and 32 (462) 
34     limit 33 to (humans and "all adult (19 plus years)") (310) 
 
Each part was specifically translated for searching the other databases (EMBASE, Web of Science, and Cochrane databases) 
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Appendix C. Quality assessment of included risk scores using the PROBAST tool 
 
Dauty, 2012 RAPT Development - - - - - - - No
Parvizi, 2014 NR Development ? ? ? - - - - No
Parvizi, 2016 NR Development + ? - - - - ? No
Parvizi, 2016 NR External validation ? ? - ? No
Bohl, 2016 ACS-NSQIP Development + ? ? ? - - ? No
Bohl, 2016 ACS-NSQIP External validation + ? ? ? ? No
Bateman, 2017 NR Development ? ? - - - - - No
+
?
-
Low risk of bias
Unclear risk of bias
High risk of bias
 
ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; NR, not reported 
 
